Soleno Therapeutics, Inc. (SLNO)

Soleno Therapeutics, Inc. (SLNO) is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, dedicated to developing novel treatments for rare diseases. Led by CEO Anish Bhatnagar, M.D., Soleno’s strategic mission is to "transform the lives of patients and families affected by rare diseases with significant unmet medical needs." The company holds a prominent industry position as the developer of DCCR (Diazoxide Choline Controlled-Release), which received FDA approval in March 2025 under the brand name VYKAT™ XR for the treatment of Prader-Willi Syndrome (PWS). The company’s vision is to build a diversified rare disease pipeline centered on its proprietary controlled-release technology. By late 2025, SLNO stock has surged, with the SLNO stock price driven by a highly successful commercial launch that saw over 1,043 patient start forms and $66 million in net product revenue in just its second full quarter of sales.

The business operations of Soleno Therapeutics are currently focused on the U.S. launch and global expansion of VYKAT XR. PWS is a complex orphan disease characterized by hyperphagia (an insatiable appetite), for which VYKAT XR is the first approved treatment targeting the underlying neurobiological causes. In fiscal 2025, the company reported over 132 million "covered lives" through successful negotiations with major commercial and government payers. A primary growth driver is the "Global Regulatory Pathway," with a Marketing Authorization Application (MAA) filed in the EU in mid-2025. The 2026 strategic roadmap focuses on "Pipeline Expansion," as the company evaluates DCCR for other rare metabolic disorders. Soleno holds a "Regulatory Moat" through its Orphan Drug Designation and its robust patent portfolio, which provides market exclusivity for PWS treatments through the next decade. With $230 million in fresh capital raised in July 2025, the company is well-funded to scale its commercial operations and pursue new indications, making SLNO stock a top-tier biotech growth play.

Soleno Therapeutics, Inc. (SLNO) is listed on the NASDAQ Global Market. For investors monitoring SLNO stock, the company’s recent entry into a $100 million accelerated share repurchase agreement in November 2025 signals management’s confidence in the long-term cash flow potential of its lead asset. The SLNO stock price is frequently volatile around quarterly sales updates and European regulatory milestones. For those tracking SLNO stock, the company’s transition from a research-focused entity to a high-growth commercial biopharma is nearly complete, positioning it as a leader in the rare disease space.